c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients

N. Zilembo, L. Mariani, A. Martinetti, R. Miceli, E. Seregni, E. Bichisao, I. La Torre, P. Pozzi, L. Ferrari, D. De Candis, V. R. Longarini, E. Bajetta, E. Bombardieri

Research output: Contribution to journalArticlepeer-review


To investigate whether c-erbB 2 serum levels may be predictive of clinical response, progression-free and overall survival in postmenopausal women with advanced breast cancer hormonally treated, 265 patients enrolled in previous clinical trials were evaluated. C-erbB 2 serum levels were assessed before the start of treatment and in a subgroup of patients also at the first response evaluation. In addition, serum CA 15.3 levels were determined. The role of c-erbB 2 was investigated by means of multiple regression models in which both c-erbB 2 and CA 15.3 values were modelled as continuous variables together with other known prognostic factors. The failure probability tended to be higher in the presence of high c-erbB 2 levels, but the trend was not statistically significant; in contrast, significant results were obtained for progression-free survival (PFS, P <0.00 1) and overall survival (OS, P = 0.014). The within-patient c-erbB 2 variation significantly predicted PFS (P = 0.006) and OS (P = 0.040). It is worth noting that c-erbB 2 and CA 15.3 baseline levels were significantly correlated and that the prognostic effect of c-erbB 2 tended to disappear in the presence of high CA 15.3 levels for PFS and OS.

Original languageEnglish
Pages (from-to)286-294
Number of pages9
Issue number4
Publication statusPublished - Aug 2002

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients'. Together they form a unique fingerprint.

Cite this